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ABSTRACT
Mammalian cleavage factor I (CF Im) is composed of two polypeptides of 25 kDa and either a 59 or 68 kDa subunit (CF Im25, CF
Im59, CF Im68). It is part of the cleavage and polyadenylation complex responsible for processing the 39 ends of messenger RNA
precursors. To investigate post-translational modifications in factors of the 39 processing complex, we systematically searched
for enzymes that modify arginines by the addition of methyl groups. Protein arginine methyltransferases (PRMTs) are such
enzymes that transfer methyl groups from S-adenosyl methionine to arginine residues within polypeptide chains resulting in
mono- or dimethylated arginines. We found that CF Im68 and the nuclear poly(A) binding protein 1 (PABPN1) were methylated
by HeLa cell extracts in vitro. By fractionation of these extracts followed by mass spectral analysis, we could demonstrate that
the catalytic subunit PRMT5, together with its cofactor WD45, could symmetrically dimethylate CF Im68, whereas pICln, the
third polypeptide of the complex, was stimulatory. As sites of methylation in CF Im68 we could exclusively identify arginines in
a GGRGRGRF or ‘‘GAR’’ motif that is conserved in vertebrates. Further in vitro assays revealed a second methyltransferase,
PRMT1, which modifies CF Im68 by asymmetric dimethylation of the GAR motif and also weakly methylates the C-termini of
both CF Im59 and CF Im68. The results suggest that native—as compared with recombinant—protein substrates may contain
additional determinants for methylation by specific PRMTs. A possible involvement of CF Im methylation in the context of RNA
export is discussed.
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INTRODUCTION
Messenger RNA precursors (pre-mRNAs) in eukaryotes are
processed extensively before they serve as templates for
protein synthesis. pre-mRNAs are cleaved at specific sites
downstream from the coding region by the cleavage and
polyadenylation complex (also called the 39 processing
complex), followed by the addition of a poly(A) extension
to the upstream cleavage fragment. A recent proteomic
analysis of a purified mammalian 39 processing apparatus
identified about 85 polypeptides (Shi et al. 2009). The core
factors of the complex are the cleavage and polyadenylation
specificity factor (CPSF) consisting of eight polypeptides:
CPSF-30, CPSF-73, CPSF-100, and CPSF-160, as well as
FIP1 (Kaufmann et al. 2004), WDR33, Rbbp6, and PP1.
Other members of the core complex are the cleavage stim-
ulation factor (CstF; 50, 64, and 77 kDa), cleavage factors I
and II (CF Im and CF IIm; two subunits each), and a poly(A)
polymerase (PAP), which is responsible for the addition of
the poly(A) tail and is assisted by nuclear poly(A) binding
protein 1 (PABPN1) for poly(A) length control (for re-
views, see Wahle and Keller 1996; Zhao et al. 1999; Martin
and Keller 2007; Ku¨hn et al. 2009; Shi et al. 2009).
CF Im is a complex that contains one polypeptide of
either 59 or 68 kDa (CF Im59, CF Im68) and a 25 kDa
homodimer (CF Im25) (Ru¨egsegger et al. 1996; Coseno
et al. 2008). Splice variants of both factors were also
described: CF Im59_S1 as a short form of CF Im59 and
CF Im68_L1 as a long form of CF Im68 with a size of 72 kDa
(previously called CF Im72 kDa) (see Fig. 1A). CF Im59/
59_S1 and CF Im68/68_L1 are encoded by two different
genes (Ru¨egsegger et al. 1996), yet share a high degree of
homology (Fig. 1). Both contain an RNA recognition motif
(RRM) fold at the N-terminus, a proline-rich region in the
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center, and an RS-like domain at the C-terminus. The CF
Im25 dimer together with one of the two larger subunits is
sufficient to stimulate cleavage, although it is not known in
what function the large subunits differ (Ru¨egsegger et al.
1996, 1998). Analysis of the subnuclear localization of CF
Im68 has identified this protein in speckles and paraspeckles
and its location varies during the cell cycle (Cardinale et al.
2007). Moreover, sequence-specific RNA binding of the CF
Im68 subunit to motifs within the 39 UTR of its own pre-
mRNA has been reported to suppress cleavage (Brown and
Gilmartin 2003). CF IIm is composed of the subunits hClp1
and hPcf11 (De Vries et al. 2000). Results of several in-
vestigations indicate an extensive network of interactions
between the factors of the 39 processing complex and other
RNA processing events such as splicing (Gunderson et al.
1994, 1998; Vagner et al. 2000; Kyburz et al. 2006) and
alternative splicing (Graveley 2000).
Post-translational modifications are present in many
factors of the mammalian pre-mRNA 39 end formation
complex (for review, see Ryan and Bauer 2008). They in-
clude phosphorylation, as found in CF Im59, Cstf-64, CstF-
77, Pcf11, CPSF-100, CPSF-160 (Olsen et al. 2006), and PAP
(Colgan et al. 1996), and lysine acetylation, which regu-
lates the interaction between CF Im25 and PAP (Shimazu
et al. 2007). In addition, CF Im68 was
shown to recruit the CBP acetyltransfer-
ase to modulate the localization of PAP
through an acetylation–deacetylation cy-
cle (Shimazu et al. 2007). Other examples
are sumoylation of PAP (Vethantham
et al. 2008) and arginine methylation of
CPSF-100, CF Im25, CF Im68, and
PABPC2, as found in a screen with the
sym10 antibody (Boisvert et al. 2003).
All these modifications are thought to
be essential for proper functioning and
regulation of 39 end processing.
Arginine methylation is a widespread
post-translational modification of pro-
teins in eukaryotes. The enzymes re-
sponsible for this activity belong to a
family of protein arginine methyltrans-
ferases (PRMTs) of which 11 different
members have been characterized (for
review, see Bedford et al. 2000; Bedford
and Richard 2005; Lee and Stallcup
2009; Nicholson et al. 2009; Wolf 2009).
PRMTs catalyze the transfer of one or
two methyl groups from the methyl
donor S-adenosyl methionine (SAM) to
arginine guanidino nitrogen atoms. In-
termediates with single methyl additions
are v-NG monomethyl arginines. There
are two classes of PRMTs that differ in
the mode of attachment of the second
methyl group. Type I PRMTs produce asymmetric v-NG,NG-
dimethylarginine and include PRMT1 (Lin et al. 1996),
PRMT2 (Qi et al. 2002; Lakowski and Frankel 2009), PRMT3
(Tang et al. 1998), PRMT4/CARM1 (Chen et al. 1999),
PRMT6 (Frankel et al. 2002), and PRMT8 (Lee et al. 2005a).
Type II methyltransferases PRMT5 (Branscombe et al.
2001), PRMT7 (Miranda et al. 2004; Lee et al. 2005b), and
PRMT9 (Cook et al. 2006) promote the formation of sym-
metric v-NG,N9G-dimethylarginines. In addition, PRMT10
and PRMT11 were predicted to represent type II PRMTs,
but have not been further characterized (for review, see
Wolf 2009, and references therein).
The cellular functions of PRMT activities are very diverse
and can involve transcriptional regulation by histone ar-
ginine methylation, RNA processing, signal transduction,
DNA repair, and protein–protein interactions, to name just
a few (for review, see Pahlich et al. 2006). In pre-mRNA
processing, mRNA transport, and translational control,
several proteins have been described to be modified by
PRMTs. An example is PABPN1, which is modified by
PRMT1, PRMT3, and PRMT6 (Fronz et al. 2008). There,
arginine methylation does not prevent self-association of
PABPN1 and it is unclear whether arginine methylation
has any effect on PABPN1 aggregation, which causes
FIGURE 1. Graphic map of CF Im59 and CF Im68 proteins. (A) Domains are indicated by
different patterns (see code under C). RRM, RNA recognition motif; Pro-rich, proline–rich
domain; GAR, glycine-arginine motif (the box of potential or cryptic GAR is white in CF Im59
because no methylation was identified); and RS/RD signifies an RS-like domain. Also indicated
as insets are included and skipped exons in alternatively spliced forms of CF Im. (B) The
protein sequence of the CF Im68 fragment in the GST-68_GR clone and with the exon included
(in parentheses) in GST-68L1_GR. (C) Fragments of CF Im59 and CF Im68 used in the
experiments. Protein segments are not drawn to exact scale.
Arginine methylation in CF Im
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oculopharyngeal muscular dystrophy (Fronz et al. 2008).
Another substrate of PRMT1 is heterogeneous nuclear
ribonucleoprotein K (hnRNP K), an activator of the ty-
rosine kinase c-Src. Asymmetric dimethylation of five dis-
tinct arginine residues in hnRNP K reduces the interaction
with and activation of c-Src and thereby inhibits the c-Src-
dependent phosphorylation of hnRNP K (Ostareck-Lederer
et al. 2006). PRMT1 appears to be the main PRMT in hu-
man cells with the largest spectrum of substrates (Pahlich
et al. 2006).
PRMT5, another well-documented methyltransferase,
acts in a complex (also called methylosome) with WD45
(also named MEP50) and pICln on many different protein
substrates (Meister et al. 2001; Friesen et al. 2002). The
PRMT5 complex is also involved in the methylation and
subsequent assembly of the spliceosomal U snRNPs, a pro-
cess that is assisted by a second complex containing the
survival of motor neuron protein SMN (Meister et al. 2002;
Neuenkirchen et al. 2008).
In this study, we systematically searched for enzymes that
modify factors of the 39 processing complex by adding
methyl groups to arginine residues. We demonstrate that
CF Im68 and PABPN1 are methylated by factors in nuclear
and cytoplasmic HeLa cell extracts. Purification of the
activity revealed that the PRMT5/WD45 complex and
PRMT1 were responsible for these activities. In addition,
the RS-like domains of CF Im59 and CF Im68 could be
methylated weakly by recombinant PRMT1. Western blots
with antisera, which recognizes symmetrically or asymmet-
rically dimethylated arginine residues, confirmed that CF
Im68 is symmetrically dimethylated and asymmetric di-
methylation is detectable only to a minor extent, whereas
CF Im59 is dimethylated asymmetrically. Possible roles of
arginine methylation in CF Im are discussed.
RESULTS
Systematic search for methyltransferase activity
acting on 39 processing factors
We initiated our study with a systematic search for
methyltransferase activity toward characterized factors of
the mammalian 39 processing complex available as recom-
binant proteins expressed in Escherichia coli or insect cells
or as proteins purified from HeLa cells. Methylation reac-
tions typically contained HeLa cell nuclear or cytoplasmic
extract, [3H]SAM, and purified proteins as substrates.
Some results are shown in Figure 2, and a list of all of
the protein substrates tested is presented in Supplemental
Table 1. Methylation was only found when CF Im68 or
PABPN1 was used as a substrate. The shortest fragment of
CF Im68 used (GST-68_GRP) encompassed a region be-
tween amino acids 191 and 407 located downstream from
the RRM and included the proline-rich domain (Fig. 2,
lanes 1,2). We also found methylation of CF Im68_L1, a CF
Im68 splice variant (see below; Fig. 3). Interestingly, with
both HeLa cell nuclear and cytoplasmic extracts no meth-
ylation of the recombinant CF Im59 protein or its frag-
ments was detected (Fig. 2, lanes 5,6; Supplemental Table
1). Methylation of PABPN1 was found to be stronger with
nuclear compared with cytoplasmic extract, whereas CF
Im68_GR was more intensely methylated by cytoplasmic
extract (Fig. 2). CF Im25 was not found to be methylated in
several assays (Supplemental Table 1; results not shown). In
a proteomics screen CF Im25 was pulled down with an
antibody against asymmetrically dimethylated arginines
(Boisvert et al. 2003), most likely as a complex with CF
Im68.
Identification of differential methylation in purified
CF Im factors
Commercially available antibodies were used to test recom-
binant and purified CF Im59 and CF Im68 proteins for the
presence of symmetric or asymmetric dimethylated argi-
nine residues (Fig. 3). In addition to CF Im68 expressed in
Picchia pastoris and partially purified CF IIm (which
contains a large proportion of CF Im), fractions of CF Im
purified from HeLa cells (Ru¨egsegger et al. 1996) were
separated on SDS gels and probed with polyclonal anti-
bodies specific for monomethylated (a-monomet), and
symmetrically (sym10) and asymmetrically dimethylated
arginines (asym24) (Boisvert et al. 2003). Both purified and
insect cell expressed CF Im proteins are weakly mono-
methylated (a-monomet panel). Purified CF Im68 was
found to be mainly symmetrically dimethylated, suggesting
that CF Im68 is a substrate for type II PRMTs (Fig. 3, sym10
FIGURE 2. Methylation activity of nuclear and cytoplasmic extracts
on recombinant and purified cleavage and polyadenylation fac-
tors. Arrowheads indicate locations of corresponding proteins on
Coomassie stained SDS gels (0.5–1 mg were loaded). NE, HeLa nu-
clear extract; CE; HeLa cytoplasmic extract.
Martin et al.
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panel, lane 3). Also, the longer form of CF Im68, CF
Im68_L1 seems to be symmetrically dimethylated (Fig. 3,
sym10 panel, lane 5); the signal is weaker because this form
of the protein is present in smaller amounts in this fraction
(Ru¨egsegger et al. 1996). A weaker signal with CF Im68 is
also seen in Figure 3, lane 3 in the asym24 panel, indicating
some asymmetric dimethylation in this protein. CF Im59
only reacted with antibodies against asymmetric dimethyl-
ation in the blot, indicating this subunit to be a substrate
for type I PRMTs. Later during this work we noticed that
antibody sym10 is partially unspecific (see below).
Tests for PRMT1 activity on CF Im68 with extracts
from PRMT1 deletion cell lines
PRMT1 was found to methylate factors involved in mRNA
translational control, such as hnRNP K (Ostareck-Lederer
et al. 2006). Because PRMT1 appeared as a likely candidate
for asymmetric methylation of CF Im, we tested methyl
transfer to the GST-68_GRP substrate with extracts of the
PRMT1 deletion embryonic stem (ES) cell line PRMT1(!/!)
(Pawlak et al. 2000). We found GST-68_GRP to be meth-
ylated by both the PRMT1(+/+) and the PRMT1(!/!) ex-
tracts (Fig. 4, lanes 2,6), although there is a slight reduction
of the signal in the PRMT1(!/!) lane. Thus, PRMT1 could
be responsible for the asymmetric part of the CF Im68-
specific methylation. The control substrate hnRNP K was
not methylated by the PRMT1(!/!) extract (Fig. 4, lane 8),
consistent with the finding that PRMT1 is the only enzyme
that methylates hnRNP K in vitro and in vivo (Ostareck-
Lederer et al. 2006). When PABPN1 was incubated with
PRMT1(!/!) extract a reduced signal could be detected that
most likely occurred from PRMT3 and PRMT6 (Fig. 4, lane
7), which are PRMTs that were shown to act on PABPN1 in
addition to PRMT1 (Fronz et al. 2008). Methylation of
PABPN1 has been extensively characterized recently (Smith
et al. 1999; Ku¨hn et al. 2003) and the protein was found to
be asymmetrically dimethylated by PRMT1, PRMT3, and
PRMT6 (Fronz et al. 2008). We therefore concentrated on
the proteins CF Im59 and CF Im68 in this study.
Purification of methyltransferase activity from HeLa
cells and identification of methyltransferase
by mass spectrometry
In order to identify CF Im68-specific methyltransferases we
first purified the activity in HeLa extracts by column
chromatography and used mass spectral analysis to detect
potential candidate PRMTs among the purified polypep-
tides. HeLa nuclear and cytoplasmic fractions were pre-
pared as described (Ru¨egsegger et al. 1996). Cytoplasmic
extract was used for the purification of the activity because
we found higher methyltransferase activity specific for CF
Im68 in this fraction compared with the nuclear extracts
(Fig. 2). Also, the prospective CF Im methyltransferase
PRMT1 was reported to be mainly concentrated in the
FIGURE 3. CF Im59 and CF Im68 subunits are differentially di-
methylated. Nuclear extract (NE) or cytoplasmic (CE) extract,
purified (CF Im purif) recombinant P. pastoris expressed CF Im (rec
CF Im) or partially purified CF IIm (CF IIm part) fractions separated
on SDS gels and blotted to NC filters were probed with an a-CF Im
antibody (reacts with both CF Im59 and CF Im68 subunits) or
a-monomethyl, sym10, or asym24 antibody. The label CF Im68/L1
points to CF Im68 (lower band) and CF Im68_L1 (upper band).
FIGURE 4. Activity of PRMT1-deficient cell extracts on protein
substrates. Cell extracts from PRMT1(+/+) and PRMT1(!/!) ES cells
were incubated with [14C]SAM and recombinant GST-68_GRP,
PABPN1, or hnRNP K (10 pmol each). Reactions were resolved on
12% SDS PAGE and methylation was detected by autoradiography.
Arginine methylation in CF Im
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cytoplasm (Herrmann et al. 2005). Starting with 20 mL
cytoplasmic extract, the CF Im68-specific PRMT activity
was purified as described in Materials and Methods with
GST-68_GRP as a test substrate. All affinity columns were
low pressure type (except for the final Phenyl Superose and
MonoQ columns) and all were run on an FPLC system
(from GE Healthcare; see Materials and Methods).
In these experiments, very weak activity specific for CF
Im59 was detected with fractionated cell extracts and was
consistently lost during the subsequent purification steps
(data not shown). Fractions from the gel filtration column
with peak activity acting on the GST-68_GRP test substrate
were then submitted to mass spectral analysis. These frac-
tions we considered ‘‘enriched’’ with respect to the concen-
tration of active PRMTs, which we estimate in the 1%–5%
range. Consistently, PRMT5 and WD45 appeared in the list
of identified peptides at positions with
high ranks in the mass spectral data
(Supplemental Table 2). When the
methylation activity was purified over
six columns (for details, see Materials
and Methods), PRMT5 and WD45 were
always present with several peptides. In
addition, when column fractions were
separated by SDS PAGE and gel slices in
the range between 68 and 75 kDa (the
predicted molecular weight of PRMT5 is
73 kDa) were analyzed, the number of
peptides originating from PRMT5 with
high scores was further increased. No
peptides of PRMT1 or other members of
the PRMT family except for PRMT5
appeared in the mass spectra. In addi-
tion, the third subunit of the methylo-
some, pICln, was never found in the
mass spectral data. This was the first in-
dication that WD45 is essential and that
the PRMT5/WD45 complex is sufficient
for methyltransferase activity acting on
CF Im68 (see below). Apparently, pICln
is loosely associated with PRMT5 and
dissociated during purification under
our conditions. In support of these find-
ings, pICln has recently been reported
to be an assembly chaperone specific for
spliceosomal Sm proteins and it appears
to be only transiently associated with
PRMT5/WD45 (Chari et al. 2008). Fur-
thermore, fraction 7 of the gel filtration
column (results of mass spectral analysis
for this fraction are listed in Supple-
mental Table 2) was used for methyla-
tion assays (see below) shown in Figure
8B, below, with substrates PABPN1 and
GST-68_GRP.
These results suggested that the GST-68_GRP substrate
was methylated by the PRMT5/WD45 complex and that
this fragment should have a GAR motif to be a true
substrate. In fact, a predicted GAR motif (GGRGRGRF)
is located at residues 201–207 of CF Im68 (Fig. 1B). This
is consistent with the results of a proteomic analysis of
arginine methylated protein complexes in which CF Im68
was identified as one of the symmetrically dimethylated
proteins that is modified at this motif (Boisvert et al. 2003).
To confirm these results we repeated the fractionation of
the HeLa cytoplasmic extract by a different scheme, first
using a HiTrap DEAE column, followed by HiTrap heparin
and Superdex-200 (see Materials and Methods), and we
probed fractions over the entire elution profile with anti-
bodies against PRMT5, WD45, pICln, and PRMT1. In addi-
tion, we tested the fractions in a methylation assay (Fig. 5).
FIGURE 5. Fractionation of the HeLa cytoplasmic extract on the HiTrap DEAE (A), HiTrap
heparin (B), and Superdex-200 (C) gel filtration columns. Fractions were probed on Western
blots with antibodies against PRMT5, WD45, pICln, and PRMT1 and an activity assay was
performed with substrates GST-68_GR and [3H]SAM. L, load; P, pellet; FT, flow through; and
PWI indicates 900 ng of the PRMT5/WD45/pICln complex. The numbers are the column
fraction numbers.
Martin et al.
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As a substrate in these assays we used
a recombinant polypeptide compris-
ing only the GAR motif (GST-68_GR)
with few flanking amino acids. The
results indicate that methylation activity
coelutes with PRMT5 and WD45 and
that pICln does not contribute to ac-
tivity. Moreover, the Western profile
for PRMT1 only partially overlaps with
the activity profile, but this does not exclude that PRMT1
contributes to the methylation of GST-68_GR.
Generation of recombinant methylosome subunits
To further analyze the methylation by the PRMT5 complex
we made several attempts to reconstitute a complex with
recombinant proteins. Expression of the three subunits in
E. coli resulted in efficient expression of PRMT5 and pICln
but with insoluble WD45. Surprisingly, the resulting
PRMT5/pICln complex was highly active in methylating
the Sm protein D1, but inactive on the GST-68_GRP
substrate (Fig. 6). Finally, a dicistronic vector construct
with PRMT5 and WD45 could successfully be expressed in
insect cells, resulting in soluble proteins. The complex was
fully reconstituted with bacterially expressed pICln if re-
quired. As expected from the mass spectrometry data, the
PRMT5/WD45 complex showed increasing levels of activity
with the GST-68_GR protein substrate (Fig. 6), and ad-
dition of pICln did not further stimulate this activity.
Because the reactions in these tests went to completion,
differences in activity with the various subcomplexes are
not obvious and kinetic studies were therefore needed to
visualize the dependence on substrate concentrations. The
results of steady-state kinetics tests clarified the contribu-
tion of pICln for CF Im68 methylation (Table 1). A protein-
substrate-dependent Michaelis constant KM was several-
fold lower when pICln was included in the reaction in
addition to PRMT5 and WD45. This suggests that the com-
plete methylosome with all three polypeptides is responsi-
ble for the methylation of CF Im68 in vivo. Also, Vmax was
more than four times higher with the ternary complex,
indicating that only the complete methylosome acts at the
full catalytic rate. Moreover, the results of a time course
experiment indicate a stimulation of the second methyl
addition to monomethylated arginines when the full meth-
ylosome complex was present in the reaction (results not
shown).
Identification of methylated arginines in CF Im68
by deletion analysis and site directed mutagenesis
To determine the substrate arginines for PRMT5 within CF
Im68, further subfragments of the CF Im68 polypeptide
were generated and, in addition, the three arginines within
the GAR motif were mutated to alanines (Fig. 1C). Methyla-
tion was found exclusively in the recombinant protein
fragment containing the GAR motif (GST-68_GR) (Fig.
7A–D, lanes 2–6), whereas the proline-rich domain (Fig.
7A–D, GST-68_P, lane 8) that contains four single RG or
GR motifs between amino acids 375 and 400 was not
methylated. In addition, fragments representing the RS
domain downstream from residue 405 and comprising the
N-terminal RRM domain were not methylated in the in
vitro assays (Fig. 7A–D, lanes 9,10).
Mutation of single arginines to alanine within the GAR
motif of CF Im68 resulted in variable effects on methylation
activity when 100 ng of recombinant PRMT5/WD45 was
present in the assay (Fig. 7A). Mutation of R206 or of all
three arginines (R202A, R204A, and R206A) resulted in
a complete loss of methylation, whereas the mutation of
R202 and R204 had less of an effect (Fig. 7A, lanes 4–6).
When the concentration of the PRMT5/WD45 complex in
the reaction was increased to 1 mg, the methylation activity
was completely lost only when all three arginines were
mutated (Fig. 7B, lane 7). And obviously, when the prod-
ucts were probed for symmetric dimethylation by sym10
antibodies, mutation of all three arginines was required to
abolish activity (Fig. 7C, lane 7).
In vitro assays with recombinant PRMT1
and PRMT5/WD45
To further analyze the different domains in CF Im59 and
CF Im68 for methylation by the recombinant PRMTs, we
FIGURE 6. The PRMT5/WD45 complex is needed for methylation
of the CF Im68 GAR motif. The control substrate Sm proteins D1/D2
(1 mg) and GST-68_GR (800 ng) were incubated in standard meth-
ylation reactions with 1 mL nuclear extract (NE) or cytoplasmic
extract (CE) or with increasing amounts of the PRMT5 complexes as
indicated. Amounts of enzyme present in the reactions were (from left
to right) PRMT5/pICln: 10, 100, and 1000 ng; PRMT5/WD45 and
PRMT5/WD45/pICln: 1, 10, and 100 ng.
TABLE 1. GST-68_GR-dependent steady-state kinetics parameters defining methyl transfer
by two different PRMT5 complexes
PRMT5 complex
KM
(mM)
Vmax
(nmol min!1 mg!1)
kcat
(min!1)
kcat/KM
(min!1 M!1)
PRMT5/WD45 0.24 0.48 0.015 75,000
PRMT5/WD45/pICln 0.037 1.97 0.059 1,594,594
Arginine methylation in CF Im
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incubated recombinant subfragments of the CF Im subunits
with PRMT1 and PRMT5/WD45. The results indicate that
PRMT1 also acts on the same GAR motif in CF Im68 as
PRMT5 does, because the fully mutated motif (GST-68_
GR_3-mut: all three arginines mutated to alanine) is not
methylated by PRMT1 (Fig. 8A, lane 3). In addition,
PRMT1 does not methylate the proline-rich and the RRM
domain of CF Im68 (Fig. 8A, lanes 2,5). However, after
longer exposure, methylation of the RS-like domains of CF
Im59 and CF Im68 by PRMT1 is clearly visible (Fig. 8A, lanes
6,8), whereas PRMT5/WD45 does not have such an activity.
In initial tests we noticed that fractions from the Super-
dex-200 column used for purification of the methylating
activity of HeLa extracts methylated recombinant but not
purified native, CF Im68 and PABPN1 proteins (Fig. 2, lanes
3,4; Fig. 8, lanes 3,4; Supplemental Table 1). We therefore
did another experiment with high concentrations of re-
combinant PRMT1 and PRMT5/WD45 to see whether
the low activity with native proteins in initial tests was just
the result of the low concentration of PRMTs present in the
HeLa cell extracts, in addition to the low substrate con-
centrations used (Fig. 8C). It indeed seems that high con-
centrations of PRMT1 and PRMT5 can also methylate the
native CF Im68 and PABPN1 proteins. However, we ob-
serve now that PRMT1, as the major PRMT for PABPN1
(Smith et al. 1999; Fronz et al. 2008), adds about half of the
SAM to the native compared with the recombinant
PABPN1 (Fig. 8C, lanes 4,5). In contrast, PRMT5/WD45
is active on both native and recombinant CF Im68 sub-
strates (Fig. 8C, lanes 6,7), consistent with our observations
that PRMT5 is the main PRMT for CF Im68. It is thus
FIGURE 7. Only arginines within the GGRGRGRF motif are meth-
ylated in CF Im68. Site directed point mutations within the GAR motif
in the GST-68_GR construct and fragments of CF Im68 were subjected
to methylation in vitro by the recombinant PRMT5/WD45 complex.
GST-68_GR_3-mut is GST-68_GR with all three arginines (202, 204,
and 206) in the GAR motif mutated to alanines. (A) One microgram
of the recombinant substrate protein was incubated with 100 ng of
PRMT5/WD45 and [3H]SAM. (B) The same as A except that 1 mg of
PRMT5/WD45 was used. (C) The same as B except that the reaction
contained cold SAM and the blot was probed with the sym10 poly-
clonal antibody against the SDM arginines. (D) Blot from C stained
with Ponceau-S.
FIGURE 8. In vitro methylation of CF Im59 and CF Im68 subfrag-
ments. (A) The gels depicted on the middle and right-hand autoradio-
grams are exposed about 10-fold longer than the autoradiogram to the
left. GST-68_GR_3-mut is GST-68_GR with all three arginines (202,
204, and 206) in the GAR motif mutated to alanines. (B) The
[3H]SAM activity test with fraction 7 of Superdex-200 column. (C)
The [3H]SAM activity test on the native and recombinant substrates.
For an explanation of substrate names above the gel see Figure 1 and
Supplemental Table 1. Assays were done in the presence of 1.3 pmol of
H6-CF Im68, 1.2 pmol of native CF Im68, 4.4 pmol of H6-PABPN1,
and 4 pmol of native PABPN1. Also included are 4.8 pmol of PRMT1
and PRMT5/WD45. The signal strength normalized to equal amounts
of the substrate are indicated as a percent below the gel and the
corresponding numbers are indicated by different fonts (normal, bold,
and italic).
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possible that native proteins contain additional informa-
tion to become more specific substrates for a particular
PRMT. Therefore, the use of truncated substrates (such as
GST-68_GR for CF Im68) always raises the question of
physiologically relevant specificity.
In order to test and assess the activity of PRMT1 and
PRMT5 on the substrates GST-68_GR, PABPN1, and D1/D2,
we compared the total methyl transfer with tritium la-
beled SAM. In addition, we determined the fractions of
symmetrical and asymmetrical dimethylation with the anti-
bodies sym10 and asym24. Results of the [3H]SAM assay
indicate that PRMT1 is slightly more active on PABPN1
when compared with PRMT5/WD45 (Fig. 9A, lanes 2,6). In
contrast, on average in several repeats of this assay, we found
PRMT5 to be 30%–50% more active on the GST-68_GR
and D1/D2 substrates when PABPN1 was normalized.
For Western blots we incubated 0.14 mM protein sub-
strates PABPN1, GST-68_GR, and D1/D2 with 20 mM
SAM with and without 1.5 mM PRMT1 or 5 mM PRMT5/
WD45, and probed the proteins blotted to nitrocellulose
with the sym10 and asym24 antibodies (Fig. 9B,C). As
expected, the PRMT5/WD45 complex indeed appears to
add a higher rate of symmetric dimethyl groups to the
substrates than PRMT1 (Fig. 9B, lanes 6–8) after subtract-
ing the signal of the control (Fig. 9B, lane 9). In contrast, in
the blot that was probed with the asym24 antibody, only
PRMT1 strongly adds asymmetric dimethyl groups to all
substrates (Fig. 9C, lanes 2–4), whereas no such methyla-
tion is detected with PRMT5/WD45 beyond the level seen
in the control (Fig. 9C, lane 9).
These results indicated that at least the sym10 antibody is
partially nonspecific because PRMT1 is not known to have
symmetric dimethylation activity. Also, both sym10 and
asym24 antibodies react weakly with the unmethylated
substrates in the control lane (Fig. 9C, lane 9). We believe
that this cross-reactivity occurs by the binding of the two
antibodies to the unmodified GAR motifs because no
binding is seen to bovine serum albumin (BSA) in the
blot, which is present at about the same concentration as
the three protein substrates [indicated by the label < (BSA)
next to the gel panels in Fig. 9].
In summary, these results show that in vitro, PRMT1
and PRMT5/WD45 mono- and dimethylate the substrates
PABPN1, GST-68_GR, and D1/D2. In addition, we con-
clude that the results obtained with dimethylation-specific
antibodies, in particular sym10, must be regarded with
caution.
Mass spectral analysis of an in vitro methylated
recombinant CF Im68_GR fragment
To further characterize the GAR motif with respect to its
methylation pattern, the recombinant GST-68_GR fusion
protein was methylated with the recombinant PRMT5/
WD45/pICln complex. Products containing symmetrically
dimethylated arginines were immunoprecipitated with
sym10 antibodies, separated by SDS gel electrophoresis,
and bands corresponding to the GST-68_GR protein were
excised and submitted to mass spectral analysis (see
Materials and Methods for details). The purpose of the
gel was to separate the GST-68_GR protein from IgG and
the methylosome components.
One tryptic peptide was detected with the GAR motif in
three peaks of additional masses, accounting for the
addition of two, three, or four methyl groups (Fig. 10).
This indicates that one of the arginines must be dimeth-
ylated; only this would allow immunoprecipitation by the
sym10 antibody. The two other species may have either one
FIGURE 9. In vitro activities of recombinant PRMT1 and the
PRMT5/WD45 complex. Assays were done in the presence of 2 pmol
each of substrates PABPN1, GST-68_GR, or D1/D2 and the reactions
were incubated for 2.5 h with 0.32 mM PRMT1 (P1) or the 0.32 mM
PRMT5/WD45 complex (P5W) as described in Materials and Meth-
ods. (A) For the [3H]SAM assay, 1.04 mCi (or 1.02 mM) [3H]SAM was
complemented with an unlabeled SAM to a total concentration of 20
mM. Protein gels were blotted to nitrocellulose and exposed to
PhosphorImager screens. (B,C) For Western blots, an unlabeled
SAM (20 mM) was present in each reaction. The blots were probed
with the sym10 and asym24 antibodies (1:2000 dilution).
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(for triple methylation) or two additional monomethylations
or a second dimethyl group, resulting in quadruple meth-
ylation. The arginine at the C-terminus of the peptide is
assumed to be unmethylated because trypsin does not cleave
the C-terminal to methylated arginines. Apparently, the pres-
ence of one doubly methylated arginine in the GGRGRGR
sequence seems to prevent cleavage or leads to inefficient
cleavage at the two other arginines within the motif.
We made several attempts to identify peptides contain-
ing methylated arginines from the GAR motif in HeLa cell
CF Im68 by mass spectrometry, but did not detect any
modified peptides with sufficient probability scores. As the
source we used either CF Im68/59/25 purified from HeLa
cells or immunprecipitated with anti-CF Im68 or the sym10
antibody and digested with trypsin and chymotrypsin.
However, we also could not identify unmethylated peptides
from the GAR region in the mass spectrum.
Proof that a dimethylated form of CF Im68 exists in HeLa
cells comes from Western blots (Fig. 3, lanes 3,4), where we
show that the sym10 antibody reacts with CF Im68 purified
from HeLa cells, but not with CF Im68 expressed in insect
cells. In addition, when we probed proteins previously
immunoprecipitated with anti-CF Im antibody with anti-
CF Im or sym10 antibodies in Western blots both signals
were comparable in intensity (data not shown).
DISCUSSION
To investigate the potential post-translational modifica-
tions in 39 processing factors we systematically tested the
addition of methyl groups to purified and recombinant
proteins by methyltransferases present in nuclear and cyto-
plasmic extracts. A first in vitro methylation screen iden-
tified two proteins as substrates, PABPN1 and CF Im68.
Chromatographic purification of methylation activity on
CF Im68 in cytoplasmic extracts led us to the mass spectral
identification of the arginine methyltransferase PRMT5
and a cofactor WD45 strongly suggesting that PRMT5 is the
major enzyme responsible for CF Im68 methylation. We could
subsequently confirm that PRMT5 and WD45 were essential
for methylation of the GAR motif in CF Im68 by use of a
reconstituted recombinant complex of the two factors, and we
found pICln to be stimulatory to this activity.
The site of methyl addition in CF Im68 could be tracked
down to a single GAR motif containing three characteristic
tandem GR motifs. We could partially dimethylate the
GAR motif arginines in vitro by use of a reconstituted
recombinant methylosome. The two subunits PRMT5 and
WD45 were essential and apparently sufficient for activity
on CF Im68. Steady-state kinetics tests indicated the
catalytic rate with the full PRMT5/WD45/pICln complex
was higher for the GST-68_GR substrate than for the
PRMT5/WD45 complex, but also the KM value was lower,
resulting in a higher catalytic efficiency, expressed as kcat/Km,
for the ternary complex (Table 1). This suggests a function
for WD45 as a specificity factor in the methylation of CF
Im68. In contrast, with a spliceosomal Sm D1/D2 hetero-
dimer we found both the PRMT5/pICln and the PRMT5/
WD45 subcomplexes to be active. pICln was recently iden-
tified as an assembly chaperone that promotes spliceosomal
FIGURE 10. Mass spectral analysis of the methylated GAR motif. Sum of the spectra from the LC/MS run of di-, tri-, and quadruply methylated
AAFPQGGRGRGRFPGAVPGGDR-peptide with a triple charge.
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snRNP formation together with the SMN complex (Chari
et al. 2008). The stimulating effect of pICln on activity with
CF Im68 is most likely caused by the stabilization of the
complex. Interestingly, no methylation of the substrate
GST-68_GR was detected when pICln was added as a po-
tential cofactor to recombinant PRMT5 in the assay (Fig.
6). It remains to be shown whether the WD45 subunit is
a specificity factor for proteins other than CF Im68.
We had indications that purified CF Im68 also contains
asymmetrically dimethylated arginines, modifications that
would require type I PRMTs. One obvious candidate for
such an activity is PRMT1. We could confirm this in
experiments with a PRMT1 deletion cell line (Fig. 4) and
also by in vitro assays with recombinant PRMT1 (Figs. 5, 8,
9). The fraction of asymmetric dimethylation within the
total arginine methylation in CF Im68 is rather small and
there could be competition between the PRMTs for a given
substrate. In our tests, methylation of the C-termini of CF
Im59 and CF Im68 by PRMT1 was weak and it cannot be
excluded that this activity is nonspecific considering the
large number of arginines in the RS-like domains present in
both factors. In addition, it is possible that other type I
PRMTs are involved in methylating these proteins. More-
over, we should point out that physiological relevance has
not been demonstrated by linking the information obtained
on the truncated substrate GST-68_GR with the native CF
Im68. The results depicted in Figure 8C confirm these con-
cerns and suggest that specificity for PRMTs can be different
in native compared with recombinant protein substrates.
In order to search for factors interacting with CF Im59
and CF Im68, we also carried out a yeast two-hybrid screen
(results not shown; see Materials and Methods for details).
We found an interaction between the SH3 domain of the
protein arginine methyltransferase PRMT2 and CF Im59,
whereas no interaction was found of any PRMT with CF
Im68. PRMT2 was shown to have asymmetric dimethyla-
tion activity on histone H4 (Lakowski and Frankel 2009).
An interaction between CF Im59 and PRMT2 was also
described in a proteome-scale screen (Rual et al. 2005).
However, we could not detect any methylation activity with
recombinant PRMT2 (results not shown).
We made several attempts to identify a function for ar-
ginine methylation in CF Im. Such functions could include
regulation of interactions with either other protein factors
or with an RNA substrate, where CF Im could also have
a role as a specialized adaptor in a pre-mRNA transcription
and processing interactome. Methylation of the GAR motif
could regulate interactions shown to exist with the SR
proteins 9G8, Srp20, and hTra2b (Dettwiler et al. 2004).
Also, interactions could be regulated by WW proteins that
bind to proline-rich motifs in their interactors (Ingham
et al. 2005). However, in extensive tests we could not find
evidence for an effect of methylated versus unmethylated
CF Im68 on its interaction with its partner CF Im25 or with
various RNA molecules (results not shown).
Another function of methylation within the CF Im68
GAR motif could be the regulation of RNA export carried
out by CF Im68, as recently reported by Ruepp et al. (2009),
who demonstrated that CF Im68 shuttles between the
nucleus and the cytoplasm in a transcription-dependent
manner and, at the same time, interacts with the mRNA
export receptor NXF1/TAP. In addition, it was postulated
that CF Im is a functional analog of the 39 end processing
factor Hrp1p (Nab4) in the yeast Saccharomyces cerevisiae
(Zhao et al. 1999). Indeed, both CF Im and Hrp1p are
involved in poly(A) site recognition and 39 processing
complex assembly and function in poly(A) site cleavage
and polyadenylation (Venkataraman et al. 2005). More-
over, both Hrp1p (Shen et al. 1998) and CF Im (Boisvert
et al. 2003; this work) can be modified by arginine
methylation. We are currently investigating a possible role
of the methylation state of CF Im on shuttling and RNA
transport by testing effects of PRMT knockdown or mu-
tagenesis in the CF Im68 GAR motif.
Furthermore, to confirm that PRMT5 is responsible for
methylation of CF Im68 we used RNAi to knock down
PRMT5 expression in HEK293 cells. The results indicated
that PRMT5 is a very stable protein in the cells. Although
we were able to dramatically reduce the level of PRMT5
after 3–5 d by siRNA transfection, the level of symmetric
dimethylation in immunoprecipitated CF Im68 or CF
Im68_L1 was not reduced (results not shown). This in-
dicates that not only the CF Im proteins, but also their
modifications are very stable. Also, our observation that
dimethylation in CF Im and of PABPN1 purified from
HeLa cells is stable and is not lost during the purification
process, and in addition cannot be further dimethylated in
vitro (Fig. 2 A,B), indicates that these modifications are
extremely stable and may not be reversible.
In summary, this work was intended to shed some light
on the pattern of arginine methylation in factors involved
in pre-mRNA 39 end processing with a focus on CF Im. We
have found two arginine methyltransferases that add
methyl groups either symmetrically or asymmetrically to
arginines within one particular motif in CF Im68. Our
results should form a basis for further research to elucidate
a function of these modifications within the complex mech-
anism of pre-mRNA 39 end processing.
MATERIALS AND METHODS
Proteins and antibodies
Nuclear and cytoplasmic extracts were prepared with minor
modifications as described previously (Dignam et al. 1983). For
the cloning of CF Im59, peptide sequencing was carried out from
the same pool of human CF Im and according to the same
procedure as described previously for CF Im68 (Ru¨egsegger et al.
1998). The sequence of CF Im59 was submitted to the GenBank
database (accession AJ275970).
Arginine methylation in CF Im
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Because both CF Im59 and CF Im68 could not be expressed as
full-length proteins in bacteria, they were produced in insect cells
or Picchia pastoris (used for Western analysis) (Fig. 3, lane 4). For
baculovirus/insect cell expression of proteins in the Bac-To-Bac
expression system (Invitrogen), coding regions or fragments of CF
Im were inserted into the transfer vector p-FASTBAC-Hta, and
generation of recombinant proteins was done as described pre-
viously (Dettwiler et al. 2004). Reconstituted recombinant CF
Im25 and CF Im68 subunits expressed in P. pastoris were described
previously (Ru¨egsegger et al. 1998). For the Western blot in Figure
3 (lane 4), 2 mL of fraction 25 from the original Phenyl Superose
column was used.
Purified CF Im from HeLa cells was described previously
(Ru¨egsegger et al. 1996). Fraction 40 (5 mL) of the final MonoQ
eluate was used for Western blots depicted in Figure 3 (CF Im
purif, lane 3). Partially purified CF I/IIm was a gift from Henk de
Vries and was described previously (De Vries et al. 2000). Fraction
43 (10 mL) of Phenyl Superose column 4 was used for Western
blots (Fig. 3; CF IIm part, lane 5).
Recombinant PRMT1 was expressed and purified as described
previously (Ostareck-Lederer et al. 2006). PRMT5 and WD45
were coexpressed in Sf21 (Spodoptera frugiperda) insect cells with
the MultiBac system (Berger et al. 2004). PRMT5 contained an
N-terminal His-tag. Harvested cells were resuspended in 20 mM
HEPES-NaOH (pH 8), 0.5 M NaCl, and 10 mM imidazole, lysed
by sonication, and the lysate clarified by centrifugation at 40,000
rpm in a 45Ti rotor. The PRMT5/WD45 heterodimer was purified
from the cleared lysate by Ni-NTA chromatography (Qiagen), fol-
lowed by dialysis and anion exchange chromatography on a 1 mL
HiTrap Q column (GE Healthcare). The final purification step
was gel filtration on a Superdex 200 column (GE Healthcare) run
in 20 mM HEPES-NaOH (pH 7.5), 0.2 M NaCl, and 5 mM DTT.
The PRMT5/pICln heterodimer was expressed in BL21(DE3)
cells induced with 1 mM IPTG at 25°C for 5 h from a tricistronic
expression plasmid encoding PRMT5, WD45, and pICln with
an N-terminal His-tag on pICln. WD45 was insoluble when
expressed with this construct. Harvested cells were resuspended
in 20 mM HEPES-NaOH (pH 8), 0.5 M NaCl, and 10 mM
imidazole, lysed by sonication, and the lysate clarified by centri-
fugation at 40,000 rpm in a 45Ti rotor. The PRMT5/pICln
heterodimer was purified from the cleared lysate by NiNTA
chromatography (Qiagen). The final purification step was gel fil-
tration on a Superdex 200 column (GE Healthcare) run in 20 mM
HEPES-NaOH (pH 7.5), 0.2 M NaCl, and 5 mM DTT.
Details for the bacterial expression and purification of pICln
have been described elsewhere (Chari et al. 2008). For reconsti-
tution of the heterotrimeric PRMT5/WD45/pICln complex, the
PRMT5/WD45 heterodimer was incubated with an equimolar
amount of bacterially expressed pICln at 4°C overnight. The re-
constitution mixture was then purified by gel filtration chroma-
tography on a Superdex 200 column (GE Healthcare) run in 20 mM
HEPES-NaOH (pH 7.5), 0.2 M NaCl, and 5 mM DTT. The Sm
proteins D1/D2 were purified as described previously (Chari et al.
2008).
The anti-PRMT5, anti-symmetric (sym10), and anti-asymmetric
arginine (asym24) antibodies were from Upstate and the anti-
monomethyl arginine antibodies (ab414) were from Abcam. The
anti-PRMT1 antibodies (MAT-B12) were from Santa Cruz. Anti-
CPSF-100 and CPSF-160 antibodies were described previously
(Jenny and Keller 1995), and the anti-CF Im antibodies were also
described previously (Ru¨egsegger et al. 1998).
In vitro protein methylation assay
In a typical methylation assay, the reaction mixture contained
between 400 and 1000 ng of a protein substrate, between 0.5 and
1 mCi S-adenosyl-L-[methyl-3H]-methionine (82 Ci/mmol from
GE Healthcare or 70.8 Ci/mmol from NEN/Perkin Elmer), and
methyltransferase preparations. The reaction was done in 10 or
15 mL total volume and incubated at 37°C for 2 h or up to over-
night. Ten microliters of 23 SDS PAGE loading buffer was added
and the products were separated on 10% or 12.5% SDS PAGE gels
depending on the size of the substrate. The proteins were then
blotted by a semidry blotting system (NOVEX from Invitrogen)
onto nitrocellulose (Protran BA85, Whatman) and the filters were
exposed to a PhosphorImager Tritium screen (GE Healthcare) for
quantification or to a Kodak BioMax MS film with a BioMax
TRANSCREEN LE intensifying screen (from Kodak) for 4 h or
overnight.
PRMT1(+/+) and PRMT1(!/!) ES cell extracts
and methylation assays
Methylation assays with ES cell extracts were done as described in
Ostareck-Lederer et al. (2006).
Fractionation of protein methyltransferase activity
The following buffers were used. Buffer A contained 25 mM Tris-
HCl (pH 7.9), 10% glycerol, 0.2 mM EDTA (pH 8.0), 0.02% NP-
40, 0.5 mM dithiotreitol (DTT), 0.5 mM phenylmethylsulfonyl
fluoride (PMSF), 0.4 mg/mL leupeptin hemisulfate, and 0.7 mg/mL
pepstatin. Buffer B was buffer A with 1 M KCl, and buffer C was
buffer A with 0.1 M KCl. All columns were run on an FPLC system
(GE Healthcare) inside a cooling cabinet.
The HeLa cytoplasmic extract was prepared as described pre-
viously (Dignam et al. 1983), except that in all buffers, Hepes-
KOH was replaced by Tris-HCl (pH 7.9). Cytoplasmic extract
corresponds to the S-100 fraction of Dignam (Dignam et al.
1983). Typically, 20 mL of dialyzed cytoplasmic extract was spun
to remove insoluble materials and applied to three 5 mL HiTrap-
DEAE-FF columns connected in series and equilibrated in buffer
C. The column was washed with 1.5 column volumes of buffer C
and protein was eluted with a linear gradient of buffers A and B
from 0.1 to 1 M KCl. Fractions were assayed with 500 ng of GST-
68-GRP and [3H]SAM as substrates. The active fractions were
pooled, dialyzed against buffer A with Hepes (pH 8.0) and 50 mM
KCl, loaded onto a 5 mL HiTrap SP column (GE Healthcare), and
eluted with a 20–1000-mM gradient; activity was in the flow
through. The flow through was directly loaded on a 1 mL HiTrap
heparin column (GE Healthcare) and eluted with a gradient of
50–1000 mM KCl (protease inhibitors were omitted from here
on). Active fractions were concentrated in a Centricon-30 device
and separated on a Superdex-200 gel filtration column (GE
Healthcare) in buffer A with 150 mM KCl. The active fractions
were subjected to ammonium sulfate precipitation (35%) by
direct addition of solid ammonium sulfate. The precipitate was
collected by centrifugation at 10,000 rpm for 30 min and the pellet
was resuspended in buffer A with 500 mM ammonium sulfate and
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loaded on a 1 mL Phenyl-Superose column (GE Healthcare). A
decreasing gradient of 500–20 mM ammonium sulfate was ap-
plied. The active fractions were dialyzed against buffer A contain-
ing 20 mM KCl, loaded on a MonoQ column (GE Healthcare),
and eluted with a 20–800 mM KCl gradient.
Yeast two-hybrid analysis of CF Im59
The coding sequence for the full-length FLJ12529 protein (Gen-
Bank accession number gi: 22450805) was PCR-amplified and
cloned into pB27 as a C-terminal fusion to LexA (N-LexA-
FLJ12529-C) and sequenced. Yeast two-hybrid screening was
performed by Hybrigenics, S.A. (http://www.hybrigenics.com).
Details of the procedure can be obtained by request from the
corresponding author.
Mass spectral analysis
The protein fractions enriched for methyltransferase activity were
ethanol precipitated before tryptic digestion. For determination of
methylarginine in the GAR motif protein GST-68_GR (4 mg) was
methylated with 1 mg PRMT5/WD45/pICln methylosome, 0.1 mM
SAM, and a buffer consisting of 40 mM Tris-HCl (pH 7.9),
200 mM NaCl, and 5 mM DTT overnight at 30°C. Dimethylated
products were immunoprecipitated with sym10 antibody coupled
to protein A Sepharose beads, 25 mL nonreducing SDS loading
buffer was added to washed beads, loaded on a 10% SDS gel,
stained with colloidal Coomassie blue (Novex kit from Invitro-
gen), gel slices containing the expected protein were isolated, and
proteins digested in gel with trypsin. Peptides were subjected to
electrospray mass spectral analysis.
RNAi
The double-stranded siRNA oligos PRMT5-1 (sense sequence:
59-GUAUGAGUGGGCUGUGACA[dT][dT]), PRMT5-2 (sense se-
quence: 59-CACAGUACUACAUGGCUUU[dT][dT], and CF Im68
(sense sequence: 59-GACCGAGAUUACAUGGAUA[dT][dT]) were
from SIGMA. For reverse transfection according to the Lipofect-
amine RNAiMAX manual (Invitrogen), 104 HEK293 cells per well
were seeded in 24-well plates with 20 nM siRNA and Lipofect-
amine-RNAiMAX (Invitrogen) in 0.6 mL OptiMEM medium
(Invitrogen), and left to grow for 3–5 d at 37°C with 5% CO2.
Steady-state kinetics
The parameters for the sum of mono- and dimethylation were
determined by titration of the substrate GST-68_GR in reactions
with [3H]SAM and either the PRMT5/WD45 or PRMT5/WD45/
pICln complex. After incubation, reactions were precipitated with
10% TCA and counted in a scintillation counter. The results were
analyzed on Lineweaver–Burk plots.
SUPPLEMENTAL MATERIAL
Supplemental material can be found at http://www.rnajournal.org.
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